CF Foundation Invests in Work on Phage Therapy for Resistant Bacteria
The Cystic Fibrosis Foundation has invested $1 million in Felix Biotechnology to support the company’s efforts to develop a phage-based therapy as an alternative to antibiotics in controlling Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). “We are incredibly honored and excited to receive this support from the CF…